Cell lines and self-amplifying RNA.
Valentrifect™ Omni+ brings the Valentris hybrid lipid nanoparticle platform to everyday cell lines and to self-amplifying RNA, the largest and hardest RNA to deliver.
The hardest RNA to deliver.
Self-amplifying RNA is several times larger than mRNA and harder to package. Valentris delivers it on the same hybrid lipid nanoparticle platform used across the Valentrifect™ family.
Matching a leading reagent at a fraction of the RNA dose cuts customers’ costliest input. We are building Omni+ to bring that advantage to cancer, drug-screening and fibroblast cell lines.
Preliminary internal data. PC3 cells transfected with firefly luciferase self-amplifying RNA; luminescence readout.
Interested in Omni+?
Tell us about your cell lines and your RNA. We would like to hear what you need.
For research use only. Not for diagnostic or therapeutic use. Lipofectamine™, MessengerMAX™ and ExpiFectamine™ are trademarks of Thermo Fisher Scientific, which is not affiliated with Valentris.